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Introduction 
To correctly assess and adjudicate melanocytic skin 
lesions to rule out melanoma via the current 
standard of care of visual assessment plus 
histopathology remains challenging even for 
pigmented lesion experts because of inherent 
limitations of image recognition [1-11]. Tools such as 
dermoscopy, confocal microscopy, or computer-
aided image analysis of skin lesions can reduce, but 
do not overcome some of these inherent limitations. 
Therapeutic challenges continue even after a 
decision has been made to biopsy a pigmented 
lesion suspicious for melanoma because  
Abbreviations:  
PLA – Pigmented Lesion Assay 
PLA(+) – PLA positive 
PLA(-) – PLA negative 
US – United States 
MPath-Dx – Melanocytic Pathology Assessment 
Tool and Hierarchy for Diagnosis 
RNA – Ribonucleic Acid 
PRAME – Preferentially Expressed Antigen in 
Melanoma 
LINC00518, LINC – Long Intergenic Non-Coding 
RNA 518 
Abstract 
The Pigmented Lesion Assay (PLA, sensitivity 91-95%, 
specificity 69-91%, negative predictive value 99%) is 
a commercially available, non-invasive gene 
expression test that helps dermatologists guide 
pigmented lesion management decisions and rule 
out melanoma. Earlier studies have demonstrated 
high clinical utility and no missed melanomas in a 3-
6-month follow-up period. We undertook the current 
investigations to provide 12-month follow-up data 
on PLA(-) tests, and to further confirm utility. A 12-
month chart review follow-up of 734 pigmented 
lesions that had negative PLA results from 5 US 
dermatology centers was performed. Thirteen of 
these lesions (1.8%) were biopsied in the follow-up 
period and submitted for histopathologic review. 
None of the lesions biopsied had a histopathologic 
diagnosis of melanoma. The test’s utility was studied 
further in a registry (N=1575, 40 US dermatology 
offices, 62 participating providers), which 
demonstrated that 99.9% of PLA(-) lesions were 
clinically monitored, thereby avoiding a surgical 
procedure, and 96.5% of all PLA(+) lesions were 
appropriately biopsied, most commonly with a 
tangential shave. This long-term follow-up study 
confirms the PLA’s high negative predictive value 
and high utility in helping guide the management of 
pigmented lesions to avoid unnecessary surgical 
procedures. 
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histologic evaluation relies on pattern recognition 
and poorly reproducible histologic criteria to 
distinguish between benign and malignant [4, 6]. 
This issue and the resulting performance of 
histopathologic assessment of melanocytic lesions 
between Melanocytic Pathology Assessment Tool 
and Hierarchy for Diagnosis (MPath-Dx) Class II and 
MPath-Dx Class IV (e.g. moderately dysplastic nevi to 
early invasive pT1a melanomas, respectively) is 
exemplified in a 2017 US study by Elmore and 
colleagues [4]. In this study, 187 pathologists 
reviewed histopathology slides of 240 melanocytic 
lesions including 118 diagnosed early-stage 
melanomas. Overall, the sensitivity of diagnosis for 
early-stage lesions (MPath-Dx Class III and IV) 
compared to consensus reads established by an 
expert panel was 65%; this was lower than expected 
by many, including healthcare providers and 
patients [4]. Interestingly, intra-observer 
reproducibility within these MPath-Dx classes 
showed similarly discouraging discordance [4]. 
Although a growing number of investigators have 
demonstrated that immunohistochemistry and 
molecular analysis techniques, such as fluorescence 
in situ hybridization, comparative genomic 
hybridization, and messenger ribonucleic acid (RNA) 
expression profiling of surgically obtained 
specimens, can help to somewhat improve our 
prediction on the behavior of melanocytic 
neoplasms, these techniques fall short of truly 
impacting pigmented lesion management because 
of their performance characteristics and because the 
tests depend on tissue samples from surgical 
biopsies [7]. Currently, and based on recent data, up 
to 90% of all biopsies are performed on benign 
lesions and are avoidable [8]. A simple, yet accurate, 
non-invasive commercially available test [12], in our 
case to guide biopsy decisions and rule out 
melanoma, is attractive to health care providers and 
patients alike. 
The recently described Pigmented Lesion Assay 
(PLA), a non-invasive PRAME (Preferentially 
Expressed Antigen in Melanoma) and LINC (Long 
Intergenic Non-Coding RNA 518,) based gene 
expression assay using an adhesive patch sample 
collection platform for obtaining epidermal RNA, is 
such a test [13-21]. This test is comprehensively 
validated (sensitivity 91-95%, specificity 69-91%, 
negative predictive value [NPV] 99%) and has 
shown encouraging data on utility as well as cost 
savings [13-21]. We previously reported on the real-
world utility of the PLA and 3-6 month follow-up data 
on 330 PLA(-) tests demonstrating high utility and 
confirming the test’s high NPV in a 3-6 month follow-
up period [14]. The focus of the current work is to 
expand the follow-up period to 12 months and to 
confirm the test’s high NPV in the real-world setting. 
Additionally, we also report on a large US registry 
study of commercially obtained results and 
management decisions to further define the test’s 
clinical utility. 
 
Methods 
We here expand on PLA follow-up and utility 
findings previously reported to include long-term 
follow-up and US registry data [13]. Approval was 
obtained from the Western-Copernicus Group’s 
independent review board. 
We enrolled 734 PLA(-) negative pigmented skin 
lesions clinically suspicious for melanoma from 5 US 
dermatology practices that use the PLA 
commercially. Each of the centers had used the PLA 
test commercially for over 12 months. A clinical 
monitor was sent to each site to conduct a detailed 
chart review for each patient once they had reached 
the 12-month follow-up time point. Charts were 
 
Figure 1. Twelve-month follow-up of Pigmented Lesion Assay 
[PLA](-) pigmented skin lesions clinically suspicious for 
melanoma (N=734). Clinicians followed the guidance of the test 
also during long-term follow-up and biopsied only 1.8% of PLA(-) 
lesions. None of the PLA(-) lesions biopsied during the follow-up 
period carried the histopathologic diagnosis of melanoma. 
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reviewed for lesion characteristics and current lesion 
disposition. Any action taken with respect to a 
previously tested lesion was recorded. If a given 
lesion was subsequently surgically biopsied, 
histopathology was reviewed. When available, the 
clinical reason for subsequent biopsy was 
ascertained. We also update findings on 61 PLA(+) 
cases, a subset of which we previously reported [13]. 
Starting in June of 2018, we initiated a registry study 
on the management of pigmented lesions after 
testing with the commercially available PLA. Forty US 
dermatology practices (and 62 providers within 
these practices including board certified 
dermatologists, primary care physicians, physician 
assistants, and nurse practitioners) participated in 
the registry and we report here on 1575 pigmented 
lesions clinically suspicious for melanoma that were 
evaluated by PLA between June and December of 
2018. The PLA results and management decisions 
(clinical monitoring of a given lesion or biopsy) were 
uploaded to a web portal. The web portal supported 
the collection of lesion PLA results, biopsy decision, 
biopsy type, and requested 3, 6, or 12 month follow 
up if the lesion was marked. Lesion location and 
patients’ sex was also recorded  
All lesion samples were obtained using a non-
invasive adhesive skin collection kit (DermTech, La 
Jolla, CA) according to package insert instructions. In 
brief, a selected pigmented lesion suspicious for 
melanoma is cleansed with an ethanol swab and 
dried, and four adhesive patches from the sample 
collection kit are applied sequentially to collect one 
sample. Gentle pressure from about 5 circular thumb 
motions ensures contact between the adhesive and 
skin; no wait time is required. To enable separation of 
lesional from non-lesional surrounding skin tissue,  
the lesion is demarcated with a marker pen on each 
one of the applied adhesive patches. Patches are 
placed in a pre-addressed courier envelope and 
shipped to a central processing laboratory without 
need for refrigeration or special handling. The 
sample collection process takes about 1-2 minutes. A 
molecular pathology report is generally available 
within 48-72 hours. 
 
Results 
Of 734 PLA(-) pigmented skin lesions clinically 
suspicious for melanoma enrolled in the study, 721 
(98.2%) were monitored without biopsy whereas 13 
(1.8%) were subjected to surgical biopsies (13 
shave/scoop procedures) within the 12-month 
follow-up period (Figure 1). Six of 13 (46.2%) surgical 
biopsies were performed at the patients’ request, 
whereas 7 biopsies were performed to provide 
clinicians with more information on changing 
lesions. Histopathology results for the biopsied PLA(-) 
lesions indicated that 11 lesions were nevi with 
various degrees of cellular atypia, one was a basal cell 
carcinoma, and one was a squamous cell carcinoma 
in situ. All lesions removed at patients’ requests were 
nevi histopathologically. In line with previously 
observed PLA use characteristics, 36.9% of studied 
patients were male and 63.1% were female (Table 1). 
Most lesions evaluated by PLA in this study were 
located on the trunk (47.5%), followed by extremities 
(35.1%), and face/head/neck areas (17.3%), (Table 1). 
Although not the focus of this study, it is 
nevertheless of interest to note that all 61 PLA(+) 
cases also recorded were surgically biopsied. Sixty-
six percent of patients returned within the 12-month 
follow-up period at varied intervals. 
Table 1. Summary of patient characteristics and lesion locations of evaluated Pigmented Lesion Assay (PLA) cases from (a), a 12-month 
follow-up chart review study of Pigmented Lesion Assay [PLA](-) lesions (N=734) and (b), a PLA registry (N=1575).  
 
 Male/Female Median Age (Years) Lesion Location 
12-Month Follow-Up PLA(-) Lesions 
(N=734) 
271 / 463 
36.9% / 63.1% 52 
Face/Head: 129 (17.5%) 
Trunk: 351 (47.5%) 
Extremities: 259 (35.0%)
Registry  
(N=1575) 
558 / 1017 
35.4% / 64.6% 48 
Face/Head: 290 (18.4%) 
Trunk: 822 (52.2%) 
Extremities: 463 (29.4%) 
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Data on 1575 patients and their lesions were 
uploaded to the registry (Figure 2; patient 
characteristics summarized in Table 1). Of these, 
1433 PLA(-) cases were reported. Notably, 1431 of 
1433 (99.9%) of patients with PLA(-) test results were 
appropriately managed with a lesion monitoring 
approach avoiding surgical procedures. Of these, 
132 (9.2%) were scheduled for follow-up in three 
months, whereas 383 (26.7%) and 732 (51.0%) were 
scheduled for follow-up in 6 and 12 months, 
respectively. In addition, 184 of patients (12.8%) 
were scheduled for follow-up at other time frames. 
Of the two PLA(-) cases subjected to surgical 
procedures, one was a melanocytic nevus subjected 
to a shave/scoop biopsy and the second was a 
squamous cell carcinoma in situ removed by MOHS 
surgery. 
Data on 142 PLA(+) tests results (9.0% of all lesions 
assessed by PLA in this cohort) were uploaded to the 
registry, and 96.5% were surgically biopsied. Of these 
biopsies, 51.1% were shave/scoop, 13.1% were 
punch, and 35.8% were excisional procedures. 
Thirty-one (21.8%) of all assessed PLA(+) had 
detectable levels of LINC and PRAME transcripts, 
whereas 85 (59.9%) showed detectable levels of the 
LINC transcript only and 26 (18.3%) had detectable 
levels of the PRAME transcript only. Table 2 
summarizes gene expression and biopsy results. 
Regarding lesions not subjected to biopsy (N=5, 
3.5% of PLA positive cases), all were LINC-only cases, 
which have a lower probability of being melanomas 
histopathologically [14]. 
 
Discussion 
The PLA is a rule-out test that helps clinicians assess 
and manage pigmented skin lesions non-invasively. 
Of critical importance for a rule-out test is the test’s 
negative predictive value or NPV, which assesses the 
probability that a negative test result was incorrect 
(leading to a false negative diagnosis). Based on 
previous validation work, the PLA has a predicted 
NPV of 99% based on a melanoma prevalence in 
biopsied pigmented lesions ranging from 3-7% [13-
15, 21]. The current study was undertaken to 
understand the long-term follow-up of PLA(-) 
pigmented lesions and help confirm the rule-out 
test’s NPV. Findings from 734 PLA(-) lesions reviewed 
at 12 months demonstrated that only 1.8% of PLA(-) 
lesions were biopsied in this follow-up period. None 
of the lesions biopsied had a melanoma diagnosis by 
histopathology consistent with PLA’s high NPV. 
Pigmented lesions that are suspicious for melanoma 
and that are being clinically followed often manifest 
visible changes, such as size increase, border 
 
 
Figure 2. Data summary from the Pigmented Lesion Assay 
registry study (N=1575, data sets collected between July and 
December of 2018).  
Table 2. Non-invasive gene expression test characteristics and selected biopsy types after Pigmented Lesion Assay [PLA](+) test results 
of PLA registry cases (N=1575). The PLA is positive if either Long Intergenic Non-Coding RNA (LINC) or Preferentially Expressed Antigen in 
Melanoma (PRAME) or both LINC and PRAME are detected.  
 
 Total PLA(+) Total LINC and PRAME(+) Total LINC(+) Total PRAME (+) 
PLA Registry 
(N=1575) 142  31 (21.8%) 85 (59.9%) 26 (18.3%) 
Biopsy Type after 
PLA(+) Test 
Shave: 70 (51.1%) 
Punch: 18 (13.1%) 
Excision: 49 (35.8%) 
No Biopsy: 5 
Shave: 11 (35.5%) 
Punch: 4 (12.9%) 
Excision: 16 (51.6%) 
No Biopsy:  0  
Shave: 49 (57.6%) 
Punch: 11 (12.9%) 
Excision: 20 (23.5%) 
No Biopsy: 5 (0.6%) 
Shave: 10 (38.5%) 
Punch: 3 (11.5%) 
Excision: 13 (50.0%) 
No Biopsy: 0 
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changes, or color variation within 3-6 months 
providing a rationale for 3-6-month follow-up 
periods [1, 22, 23]. Thus, this 12-month follow-up 
period should be sufficient for any new changes to 
manifest, indicating the presence of an emerging 
melanoma in a previously tested PLA(-) lesion. In 
addition, patients with atypical pigmented lesions 
that are being followed are instructed to identify 
changes that may indicate the presence of 
melanoma making patient concern about a 
pigmented lesion an additional risk factor for 
melanoma that can trigger assessment by biopsy [25, 
26]. We therefore believe the results of this study 
reflect and further support the high NPV of the PLA. 
Inherent limitations of the data presented include 
the assumption that lesions of patients not returning 
to follow-up visits at the site of PLA testing within a 
12-month follow-up period are true negatives. 
Additionally, we cannot rule out that some PLA(-) 
lesions may not have been adequately re-assessed 
within the 12-month follow-up period and we 
recommend erring on the side of caution and 
surgically biopsying a lesion in question if additional 
risk factors and further clinical suspicion or patient 
concern mandate such a step. Further limitations 
inherent to studies designed to assess melanoma 
rule-out tests and platforms in real-world settings 
include the low prevalence of melanoma compared 
to how common benign lesions of clinically similar 
appearance are in given target populations. 
However, it is comforting to consider that the non-
invasive gene expression platform used here lends 
itself to validation study comparisons that can 
exceed the quality level of randomized control 
groups. With this platform it is possible to obtain 
non-invasive gene expression information and 
histopathology reads from the same lesion [13]. The 
performance of the PLA relative to consensus reads 
(91% sensitivity) compares favorably to primary site 
histopathology performance (84% sensitivity), [13, 
21]. The PLA also reduces the number needed to 
biopsy (NNB, the number of biopsies needed to 
detect a melanoma) by a factor of about 10 from 25 
to 2.7 [7, 14, 21]. Cost savings of the PLA are primarily 
driven by a reduction in initial biopsies and excisions 
as well as reduced stage-related treatment costs 
from missing fewer melanomas. A recent cost 
savings analysis by Hornberger and Siegel 
demonstrates that a cost reduction of 47% per 
assessed lesion suggestive of melanoma versus the 
current histopathologic standard of care is 
achievable if the PLA priced at $500 per test is used 
[20]. Although pigmented lesions can evolve over 
time, it is helpful to again contemplate that only 13 
of 721 or 1.8% of PLA(-) lesions followed for 12 
months were surgically biopsied for any reason (6 of 
13 were biopsied at patients’ requests). These data 
sets appear to suggest that the pool of cases where 
repeat PLA testing may be considered as an 
alternative to the performed surgical biopsies in a 
real-world setting is very small. 
Regardless of the assessment used for the 
management of atypical pigmented lesions, routine 
clinical follow up is a critical component of quality 
care. Surveillance follow-up schedules for monitored 
or potential new lesions vary depending on clinical 
setting, physician specialty, stage of disease, number 
and nature of nevi, and risk factors [22, 23]. In the 
absence of evidence-based guidelines, many 
clinicians arrange follow-up according to a schedule 
with which they and their patients are most 
comfortable and surveillance plans generally include 
a follow-up after 3, 6, or 12 months as also evidenced 
by data from follow-up periods in our own registry 
study presented here [22, 23]. The vast majority of 
planned pigmented lesion follow-up visits therefore 
fall within the conservatively chosen 12-month 
period of the chart review study that is at the core of 
the data presented here. 
Understanding the clinical utility of a novel 
diagnostic test or diagnostic aid relative to the 
established standard of care is paramount to assess 
how a test is used in clinical practice and to evaluate 
the test’s impact on clinical management and 
patient benefit. In the presented registry study, 
99.9% of PLA(-) cases were scheduled for follow up 
surveillance within a 12-month time period. Only 
two of 1433 PLA(-) lesions (0.1%) were not observed 
but biopsied or excised. One was a nevus that was 
biopsied and the other case was a squamous cell 
carcinoma in situ removed via MOHS surgery where 
the PLA may have been used to rule out melanoma 
prior to selecting a MOHS procedure. The clear 
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clinical benefit is that these patients avoided a 
surgical biopsy procedure as well as the attendant 
risks of scarring, infection, bleeding, and abnormal 
wound healing, which may occur in a small subset of 
patients, but which is magnified by the extremely 
high number of surgical biopsies performed on 
pigmented lesions [7, 21]. Perhaps even more 
importantly, initial surgical biopsy procedures often 
lead to wider margin excisional removal procedures 
owing to uncertainty of the initial histopathologic 
diagnosis. This is related to challenges associated 
with histopathologic assessment, including limited 
lesion sampling of only 1-2% of the biopsied tissue, 
overlapping diagnostic criteria between atypical 
nevi and early stage melanoma, and variability in 
assessment of cellular atypia [4, 6, 27, 28]. These wide 
excisional procedures are much more significant and 
often require closure repair. Up to 40% of initial 
biopsy procedures may be followed with a wider 
margin excision. Therefore, reducing initial surgical 
biopsies has the added clinical benefit of reducing 
follow-up full excisions [27]. 
Of equal importance is ensuring that PLA(+) tests are 
appropriately followed with a surgical biopsy. In the 
reported registry study, 96.5% or 137 of 142 PLA(+) 
cases were biopsied. It is of interest to note that of 
the 5 PLA(+) registry study cases not biopsied but 
rather monitored, all were LINC only positive. These 
cases came from two clinicians at two sites whereas 
the other 60 participating clinicians biopsied all 
PLA(+) lesions. Tests with only this single transcript 
carry a lower probability of being diagnosed 
histopathologically as melanoma than tests with the 
PRAME transcript only, or results with both 
transcripts detected [14]. Figure 3 depicts a 
simplified model on how the PLA transcripts LINC 
and PRAME are involved in the evolution of 
melanocytic lesions. The model attempts to convey 
how initial molecular changes at the DNA and RNA 
level are followed by microscopic changes that 
enable histopathologic assessment and ultimately 
manifest themselves as macroscopic changes 
including ABCDE criteria frequently used to clinically 
assess pigmented skin lesions [1-4, 13-15]. Overall, 
93% of PLA results positive for both LINC and PRAME 
are diagnosed histopathologically as in situ or 
invasive melanomas. PRAME-negative only and 
LINC-negative only lesions are melanomas 
histopathologically in 50% and 7%, respectively [14]. 
Both targets are known to be overexpressed in 
melanoma and mechanistically PRAME promotes 
melanoma progression by interfering with retinoic 
acid receptor signaling and LINC is a regulator of 
oncogenesis affecting melanoma proliferation and 
invasion [13]. All PRAME only or LINC and PRAME 
double positive cases were biopsied at all registry 
study sites. More excisional biopsies were performed 
on double positive lesions and PRAME positive 
lesions, which have a higher probability of being 
diagnosed as melanomas by histopathologic 
assessment than on LINC only lesions, as mentioned 
above (Table 2). These findings further support that 
clinicians appropriately follow the guidance of the 
test and that the types of biopsy conducted were 
consistent with US practice. Furthermore, it is also of 
interest to note that most lesions evaluated by PLA 
were located on the trunk followed by extremities, 
suggesting that the use of PLA testing was not 
limited to cosmetically sensitive areas.  
The current standard of care for the management of 
atypical pigmented lesions attempts to rule out  
 
Figure 3. Simplified model on Long Intergenic Non-Coding RNA 
(LINC)and Preferentially Expressed Antigen in Melanoma 
(PRAME) gene expression in the evolution of melanocytic lesions. 
The model depicts how initial molecular changes at the DNA (2) 
and RNA level (3) are followed by microscopic changes (4) that 
enable histopathologic assessment and are followed by 
macroscopic changes (5) captured within ABCDE criteria 
frequently used to clinically assess pigmented skin lesions. [1-4, 
13-15].
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melanoma via visual assessment followed by surgical 
biopsy and histopathology [1-11]. The aim of this 
assessment is to identify melanoma at the earliest 
stages when a high cure rate is possible by wide 
excision, while monitoring lesions that don’t need to 
be biopsied [22]. The current visual standard of care 
pathway has an NPV for early stage melanoma that 
ranges from 75%-89% [4-8], although the real world 
NPV may be higher owing to the use of special stains 
on lesions with difficult histopathology and the 
default to wide excisions in challenging cases. The 
PLA provides an alternative assessment that 
demonstrates a high NPV (99%) while avoiding 
surgical procedures.  
It is furthermore of interest to note that there is a 
growing body of evidence that not only clinicians, 
but also dermatopathologists benefit from the 
availability of melanoma-associated molecular risk 
factor information when they approach diagnostic 
decisions on pigmented lesions since primarily 
image recognition-based assessment of pigmented 
lesions remains challenging even for experts [24]. 
Providing non-invasively obtained results of PLA 
testing of clinically ambiguous pigmented lesions to 
pathologists can enable pathologists to even more 
closely evaluate borderline malignant lesions for  
 
histopathologic evidence of malignancy (C. 
Cockerell MD, personal communication). 
 
Conclusion 
Twelve-month follow-up data and findings from a 
large US registry study described here confirm the 
PLA’s high clinical utility and high negative 
predictive value. Clinicians follow the guidance of 
the test and rely on it during long-term follow-up. 
PLA(-) lesions are monitored clinically and generally 
not biopsied, avoiding unnecessary surgical 
procedures; PLA(+) lesions are biopsied as intended. 
The PLA is a test that transforms the current 
diagnostic pathway from one that is subjective, 
invasive, and of low accuracy to one that is objective, 
non-invasive, and highly accurate. 
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